Lung cancer

Osimertinib could be new standard of care for EGFRm NSCLC

Osimertinib has been shown to be useful in patients with early stage non-small cell lung cancer (NSCLC) with resectable disease, according to a ‘practice-changing’ presentation at the 2020 ASCO Virtual Scientific Program. Professor Roy Herbst, chief of medical oncology from Yale Cancer Centre, said the findings built on the known efficacy and safety of the ...

Already a member?

Login to keep reading.

© 2021 the limbic